Aderans Research Reaches Major Milestone in Phase 2 Clinical Study Enrollment

Aderans Research reached a major milestone this month with the completion of enrollment in one of its key Phase 2 clinical protocols.

Atlanta, GA (PRWEB) March 28, 2012

Aderans Research reached a major milestone this month with the completion of enrollment in one of its key Phase 2 clinical protocols. A total of more than 350 subjects across the country are enrolled in the trial, which evaluates the effect of Aderans’ unique Ji Gami™ family of cell products on pattern hair loss.

“We’re thrilled to reach this landmark in our research,” said Vern Liebmann, Aderans Research Chief Operating Officer. “We are looking forward to sharing the advances we’ve made in the field of hair regeneration.”

Aderans expects to tabulate, analyze and present their findings at the conclusion of the trial. In the meantime, more clinical protocols are in the works to test additional products coming down the pipeline and see how they might benefit patients with male and female pattern hair loss.

“Our cell engineering solutions offer a completely new approach to treatment for the millions of people who suffer from hair loss,” said Aderans Research Chief Executive Officer Ken Washenik, M.D., Ph.D. “The results to date are promising, and with the enrollment complete in this Phase 2 protocol, we’re getting even closer to a solution.”

Worried about hair loss? Worry no more Leimo is an Australian-based company that has produced a line of treatments to prevent further hair loss/thinning and restore hair without any side effects. Read more on LEIMO